Truist Securities analyst Bill Chappell downgrades Keurig Dr Pepper (NASDAQ:KDP) from Buy to Hold and announces $40 price target.
Oppenheimer Upgrades Editas Medicine to Outperform, Raises Price Target to $80
Oppenheimer analyst Jay Olson upgrades Editas Medicine (NASDAQ:EDIT) from Perform to Outperform and raises the price target from $42 to $80.